Receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well-controlled type 2 diabetes

Journal of Periodontology

Volumn 81, Issue 10, 2010, Pages 1455-1465

  Santos, Vanessa Renata ^a   Lima, Jadson Almeida ^a   Goncxalves, Tiago Eduardo Dias ^a   Bastos, Marta Ferreira ^a   Figueiredo, Luciene Cristina ^a   Shibli, Jamil Awad ^a   Duarte, Poliana Mendes ^a  

^a GUARULHOS UNIVERSITY   (Brazil)

Author keywords

Chronic periodontitis; Diabetes mellitus; Osteoprotegerin; Rank ligand; Root planing

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CHEMISTRY; CHI SQUARE DISTRIBUTION; CHRONIC PERIODONTITIS; FEMALE; GINGIVITIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONPARAMETRIC TEST; PREVENTIVE DENTISTRY; TOOTH PLAQUE;

ADULT; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CHRONIC PERIODONTITIS; DENTAL PLAQUE; DENTAL SCALING; DIABETES MELLITUS, TYPE 2; FEMALE; GINGIVAL CREVICULAR FLUID; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND; STATISTICS, NONPARAMETRIC;

EID: 78249246646     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2010.100125     Document Type: Article

References (47)

1. Israili ZH. Advances in the treatment of type 2 diabetes mellitus. Am J Ther 2009. [Epub ahead of print].
2. Novak MJ, Potter RM, Blodgett J, Ebersole JL. Periodontal disease in Hispanic Americans with type 2 diabetes. J Periodontol 2008;79:629-636.
3. Salvi GE, Carollo-Bittel B, Lang NP. Effects of diabetes mellitus on periodontal and peri-implant conditions: Update on associations and risks. J Clin Periodontol 2008;35(Suppl. 8) 398-409.
4. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002;30:182-192.
5. Lim LP, Tay FB, Sum CF, Thai AC. Relationship between markers of metabolic control and inflammation on severity of periodontal disease in patients with diabetes mellitus. J Clin Periodontol 2007;34:118-123.
6. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol 2008;79(Suppl. 8) 1569-1576.
7. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005;208:30-49.
8. Taubman MA, Valverde P, Han X, Kawai T. Immune response: The key to bone resorption in periodontal disease. J Periodontol 2005;76(Suppl. 11) 2033-2041.
9. Wright HL, McCarthy HS, Middleton J, Marshall MJ. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009;2:56-64.
10. Crotti T, Smith MD, Hirsch R, et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38:380-387.
11. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-169.
12. Vernal R, Chaparro A, Graumann R, Puente J, Valenzuela MA, Gamonal J. Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004;75:1586-1591.
13. Lu HK, Chen YL, Chang HC, Li CL, Kuo MY. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 2006;41:354-360.
14. Bostanci N, Ilgenli T, Emingil G, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: Implications of their relative ratio. J Clin Periodontol 2007;34:370-376.
15. Bostanci N, Ilgenli T, Emingil G, et al. Differential expression of receptor activator of nuclear factorkappaB ligand and osteoprotegerin mRNA in periodontal diseases. J Periodontal Res 2007;42:287-293.
16. Duarte PM, Neto JB, Casati MZ, Sallum EA, Nociti FH Jr. Diabetes modulates gene expression in the gingival tissues of patients with chronic periodontitis. Oral Dis 2007;13:594-599.
17. Lappin DF, Eapen B, Robertson D, Young J, Hodge PJ. Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. J Clin Periodontol 2009;36:634-641.
18. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
19. Araujo MW, Hovey KM, Benedek JR, et al. Reproducibility of probing depth measurement using a constant-force electronic probe: Analysis of inter-and intraexaminer variability. J Periodontol 2003;74:1736-1740.
20. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J 1975;25:229-235.
21. Wara-aswapati N, Surarit R, Chayasadom A, Boch JA, Pitiphat W. RANKL upregulation associated with periodontitis and Porphyromonas gingivalis. J Periodontol 2007;78:1062-1069.
22. Reddi D, Bostanci N, Hashim A, et al. Porphyromonas gingivalis regulates the RANKL-OPG system in bone marrow stromal cells. Microbes Infect 2008;10:1459-1468.
23. Liu D, Xu JK, Figliomeni L, et al. Expression of RANKL and OPG mRNA in periodontal disease: Possible involvement in bone destruction. Int J Mol Med 2003;11:17-21.
24. Mahamed DA, Marleau A, Alnaeeli M, et al. G (-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 2005;54:1477-1486.
25. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerindeficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
26. Hein GE. Glycation endproducts in osteoporosis-Is there a pathophysiologic importance? Clin Chim Acta 2006;371:32-36.
27. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-15004.
28. Lalla E, Lamster IB, Drury S, Fu C, Schmidt AM. Hyperglycemia, glycoxidation and receptor for advanced glycation endproducts: Potential mechanisms underlying diabetic complications, including diabetesassociated periodontitis. Periodontol 2000 2000;23:50-62.
29. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000;105:1117-1124.
30. Alblowi J, Kayal RA, Siqueira M, et al. High levels of tumor necrosis factor-alpha contribute to accelerated loss of cartilage in diabetic fracture healing. Am J Pathol 2009;175:1574-1585.
31. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
32. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membranebound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775.
33. Yoshida T, Flegler A, Kozlov A, Stern PH. Direct inhibitory and indirect stimulatory effects of RAGE ligand S100 on sRANKL-induced osteoclastogenesis. J Cell Biochem 2009;107:917-925.
34. Ding KH, Wang ZZ, Hamrick MW, et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 2006;340:1091-1097.
35. Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 2007;113:154-161.
36. Tervonen T, Karjalainen K. Periodontal disease related to diabetic status. A pilot study of the response to periodontal therapy in type 1 diabetes. J Clin Periodontol 1997;24:505-510.
37. Christgau M, Palitzsch KD, Schmalz G, Kreiner U, Frenzel S. Healing response to non-surgical periodontal therapy in patients with diabetes mellitus: clinical, microbiological, and immunologic results. J Clin Periodontol 1998;25:112-124.
38. Santos VR, Lima JA, De Mendonçxa AC, Braz Maximo MB, Faveri M, Duarte PM. Effectiveness of full-mouth and partial-mouth scaling and root planing in treating chronic periodontitis in subjects with type 2 diabetes. J Periodontol 2009;80:1237-1245.
39. Faria-Almeida R, Navarro A, Bascones A. Clinical and metabolic changes after conventional treatment of type 2 diabetic patients with chronic periodontitis. J Periodontol 2006;77:591-598.
40. Navarro-Sanchez AB, Faria-Almeida R, Bascones-Martinez A. Effect of non-surgical periodontal therapy on clinical and immunological response and glycaemic control in type 2 diabetic patients with moderate periodontitis. J Clin Periodontol 2007;34:835-843.
41. Syrjälä AM, Kneckt MC, Knuuttila ML. Dental selfefficacy as a determinant to oral health behaviour, oral hygiene and HbA1c level among diabetic patients. J Clin Periodontol 1999;26:616-621.
42. Goncxalves D, Correa FO, Khalil NM, de Faria Oliveira OM, Orrico SR. The effect of non-surgical periodontal therapy on peroxidase activity in diabetic patients: A case-control pilot study. J Clin Periodontol 2008;35:799-806.
43. Promsudthi A, Pimapansri S, Deerochanawong C, Kanchanavasita W. The effect of periodontal therapy on uncontrolled type 2 diabetes mellitus in older subjects. Oral Dis 2005;11:293-298.
44. Janket SJ, Wightman A, Baird AE, Van Dyke TE, Jones JA. Does periodontal treatment improve glycemic control in diabetic patients? A meta-analysis of intervention studies. J Dent Res 2005;84:1154-1159.
45. Hassumi MY, Silva-Filho VJ, Campos-Júnior JC, et al. PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int Immunopharmacol 2009;9:1150-1158.
46. Buduneli N, Buduneli E, Kütükçxüler N. Interleukin-17, RANKL, and osteoprotegerin levels in gingival crevicular fluid from smoking and non-smoking patients with chronic periodontitis during initial periodontal treatment. J Periodontol 2009;80:1274-1280.
47. Jin Q, Cirelli JA, Park CH, et al. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol 2007;78:1300-1308.